Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-04
2005-01-04
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S472000, C514S546000, C514S551000
Reexamination Certificate
active
06838471
ABSTRACT:
A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
REFERENCES:
patent: 5567724 (1996-10-01), Kelleher et al.
patent: 5604231 (1997-02-01), Smith et al.
patent: 5709853 (1998-01-01), Iino et al.
patent: 5733255 (1998-03-01), Dinh et al.
patent: 6096728 (2000-08-01), Collins et al.
patent: 6166048 (2000-12-01), Bencherif
patent: 6610713 (2003-08-01), Tracey
Antonica, A., et al., “Vagal Control of Lymphocyte Release from Rat Thymus,”Journal of the Autonomous Nervous System, 48(3):187-197 (1994).
Borovikova, L.V., et al., “Role of the Vagus Nerve in the Anti-Inflammatory Effects of CNI-1493,”Proceedings of the Annual Meeting of Professional Research Scientists: Experimental Biology, Abstract 97.9 (2000).
Borovikova, L.V., et al., “Vagus Nerve Stimulation Attenuates the Systemic Inflammatory Response to Endotoxin,”Nature, 405(25):458-462 (2000).
Borovikova, L. V., et al., “Role of Vagus Nerve Signaling in CNI-1493-Mediated Suppression of Acute Inflammation,”Autonomic Neuroscience: Basic and Clinical, 85:141-147 (2000).
Fleshner, M., et al., “Thermogenic and Corticosterone Responses to Intravenous Cytokines (IL-1 Beta and TNF-Alpha) are Attenuated by Subdiaphragmatic Vagotomy,”Journal of Neuroimmunology, 86:134-141 (1998).
Gaykema, R.P., et al., “Subdiaphragmatic Vagotomy Suppresses Endotoxin-Induced Activation of Hypothalamic Corticotropin-Releasing Hormone Neurons and ACTH Secretion,”Endocrinology, 136(10):4717-4720 (1995).
Guslandi, M., “Nicotine Treatment for Ulcerative Colitis,”Br. J. Clin. Pharmacol., 48:481-484 (1999).
Kawashima, K. and Fujii, T., “Extraneuronal Cholinergic System in Lymphocytes,”Pharmacology&Therapeutics, 86:29-48 (2000).
Madretsma, G.S., et al., “Nicotine Inhibits the in vitro Production of Interleukin 2 and Tumour Necrosis Factor-Alpha by Human Mononuclear Cells,”Immunopharmacology, 35(1):47-51 (1996).
Romanovsky, A.A., et al., “The Vagus Nerve in the Thermoregulatory Response to Systemic Inflammation,”American Journal of Physiology, 273(1):R407-413 (1997).
Sandborn, W.J., et al., “Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis,”Annals of Internal Medicine, 126(5):364-371 (1997).
Sato, E., et al., “Acetylcholine Stimulates Alveolar Macrophages to Release Inflammatory Cell Chemotactic Activity,”Am. J. Physiol., 274:L970-79 (1998).
Sato, K.Z., et al., “Diversity of mRNA Expression for Muscarinic Acetylcholine Receptor Subtypes and Neuronal Nicotinic Acetylcholine Receptor Subunits in Human Mononuclear Leukocytes and Leukemic Cell Lines,”Neuroscience Letters, 266:17-20 (1999).
Scheinman, R.I., et al., “Role of Transcriptional Activation of I-kappaB-aleph in Mediation of Immunosuppression by Glucocorticoids,”Science, 270:283-286 (1995).
Sher, M.E., et al., “The Influence of Cigarette Smoking on Cytokine Levels in Patients with Inflammatory Bowel Disease,”Inflammatory Bowel Diseases, 5(2):73-78 (1999).
Steinlein, O., “New Functions for Nicotine Acetylcholine Receptors?,”Behavioural Brain Res., 95:31-35 (1998).
Sternberg, E.M. (Series Editor), “Neural-immune Interactions in Health and Disease,”The Journal of Clinical Investigation, 100(11):2641-2647 (1997).
Sykes, A.P., et al., “An Investigation into the Effect and Mechanisms of Action of Nicotine in Inflammatory Bowel Disease,”Inflamm. Res., 49:311-319 (2000).
Toyabe, S., et al., “Identification of Nicotinic Acetylcholine Receptors on Lymphocytes in the Periphery as well as Thymus in Mice,”Immunology, 92:201-205 (1997).
Van Dijk, A.P.M., et al., “Transdermal Nicotine Inhibits Interleukin 2 Synthesis by Mononuclear Cells Dervied from Healthy Volunteers,”European Journal of Clinical Investigation, 28:664-671 (1998).
Watkins, L.R. and Maier, S.F., “Implications of Immune-to-Brain Communication for Sickness and Pain,”PNAS96(14):7710-7713 (1999).
Watkins, L.R. et al., “Blockade of Interleukin-1 Induced Hyperthermia by Subdiaphragmatic Vagotomy:Evidence for Vagal Mediation of Immune-Brain Communication,”Neuroscience Letters, 183:27-31 (1995).
Whaley, K., et al., “C2 Synthesis by Human Monocytes is Modulated by a Nicotinic Cholinergic Receptor,”Nature, 293:580-582 (1981).
Hamilton Brook Smith & Reynolds P.C.
Henley III Raymond J.
North Shore-Long Island Jewish Research Institute
LandOfFree
Inhibition of inflammatory cytokine production by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of inflammatory cytokine production by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of inflammatory cytokine production by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3404074